Retatrutide vs AOD-9604
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and AOD-9604 (Advanced Obesity Drug). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | AOD-9604 Advanced Obesity Drug, Tyr-hGH Fragment 176-191 |
|---|---|---|
| FDA Status | Phase 3 (NDA expected late 2026) | Phase 2 (failed; reclassification pending) |
| Category | Weight Loss | Weight Loss |
| Primary Use | Obesity and weight management | Fat loss and metabolism enhancement |
| Weight Loss % | 28.7% | N/A |
| Monthly Cost | $1,200 - $1,500/mo | $30 - $60/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 300mcg daily |
| Frequency | Weekly | Daily |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without affecting blood sugar or IGF-1 |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Low |
| Clinical Trial Phase | Phase 3 | Phase 2 |
Key Differences
- 1Retatrutide has clinical weight loss data (28.7%), while AOD-9604 is not primarily indicated for weight loss.
- 2AOD-9604 is generally more affordable ($30 - $60/mo) compared to Retatrutide ($1,200 - $1,500/mo).
- 3Retatrutide is dosed weekly, while AOD-9604 is daily.
- 4Retatrutide has high-quality evidence, while AOD-9604 has low-quality evidence.
Which Is Better For...
AOD-9604
More budget-friendly option with lower monthly costs
Retatrutide
More convenient dosing schedule (weekly)
AOD-9604
Fewer commonly reported side effects
Retatrutide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 (NDA expected late 2026) | Eli Lilly |
| AOD-9604 | $30 - $60/mo | Phase 2 (failed; reclassification pending) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. AOD-9604 works via Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis. They differ in FDA approval status, efficacy data, and cost.
Retatrutide has demonstrated 28.7% average weight loss in clinical trials. AOD-9604 is not primarily used for weight loss.
Retatrutide typically costs $1,200 - $1,500/mo, while AOD-9604 costs $30 - $60/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). AOD-9604 is not FDA-approved (Phase 2 (failed; reclassification pending)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of AOD-9604 include Injection site reactions, Headache, Chest tightness (rare). Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuideAOD-9604 is a modified peptide fragment of the C-terminus of human growth hormone (amino acids 176-191). It was designed to retain the fat-burning properties of HGH while avoiding effects on blood sug...
View Full AOD-9604 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and AOD-9604 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.